Ownership Capital B.V. Sells 13,052 Shares of Insulet Co. (NASDAQ:PODD)

Ownership Capital B.V. cut its holdings in Insulet Co. (NASDAQ:PODD - Free Report) by 6.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 180,842 shares of the medical instruments supplier's stock after selling 13,052 shares during the quarter. Insulet comprises about 1.7% of Ownership Capital B.V.'s investment portfolio, making the stock its 22nd biggest holding. Ownership Capital B.V. owned 0.26% of Insulet worth $47,212,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. raised its position in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after acquiring an additional 58 shares in the last quarter. Venturi Wealth Management LLC raised its holdings in Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock worth $36,000 after buying an additional 133 shares during the period. Friedenthal Financial acquired a new stake in Insulet during the 4th quarter worth about $57,000. TD Private Client Wealth LLC raised its holdings in Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock worth $53,000 after buying an additional 56 shares during the period. Finally, Versant Capital Management Inc raised its holdings in Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier's stock worth $80,000 after buying an additional 157 shares during the period.

Insider Activity at Insulet

In related news, CAO Lauren Budden sold 915 shares of the company's stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the company's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company's stock, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Stifel Nicolaus boosted their price objective on Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a report on Friday. JPMorgan Chase & Co. boosted their price objective on Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a report on Thursday, December 12th. Wells Fargo & Company boosted their price objective on Insulet from $305.00 to $322.00 and gave the stock an "overweight" rating in a report on Friday. Sanford C. Bernstein started coverage on Insulet in a report on Wednesday, November 6th. They set an "outperform" rating and a $300.00 price objective on the stock. Finally, Barclays boosted their price target on Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, Insulet presently has a consensus rating of "Moderate Buy" and an average target price of $289.06.

Insulet Stock Performance

Shares of PODD stock traded down $5.49 during trading hours on Friday, reaching $282.80. 1,410,496 shares of the company's stock were exchanged, compared to its average volume of 574,159. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The stock has a market capitalization of $19.84 billion, a P/E ratio of 48.42, a P/E/G ratio of 3.56 and a beta of 1.23. The business has a fifty day moving average price of $272.98 and a 200-day moving average price of $247.11. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. Analysts predict that Insulet Co. will post 3.22 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.